New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.

KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.

Lilly will hope Foundayo continues its growing dominance over Novo Nordisk in the obesity drug market. Credit: Michael Vi/Shutterstock.com. The US Food and Drug Administration (FDA) has approved Eli ...

Merck KGaA has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.

Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas.

Biogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.

Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.

A lack of effective non-invasive ways to diagnose endometriosis contributes to delayed intervention and limits the potential for clinical development of therapeutics. Credit: H_Ko/Shutterstock.com.

Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.

Symeres has partnered with Ambagon Therapeutics on molecular glue research in colorectal cancer to target diseases considered hard to treat.

Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.

At the 2026 ACC Scientific Session in New Orleans, researchers presented a meta-analysis of three randomized trials (1,264 ...